NOCDURNA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $210,090 | 10,333 | 6,082 |
| 2022 | $488,406 | 23,129 | 8,588 |
| 2021 | $214,014 | 597 | 335 |
| 2020 | $880,205 | 370 | 80 |
| 2019 | $2.9M | 3,876 | 1,623 |
| 2018 | $1.4M | 1,178 | 783 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 712 | 76.3% |
| Food and Beverage | $717,379 | 38,220 | 11.8% |
| Honoraria | $249,530 | 134 | 4.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $228,318 | 78 | 3.8% |
| Consulting Fee | $174,931 | 28 | 2.9% |
| Travel and Lodging | $63,961 | 306 | 1.1% |
| Education | $1,314 | 5 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults | Ferring Pharmaceuticals AS | $2.5M | 0 |
| A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults | Ferring International Pharmascience Center US | $2.1M | 0 |
Top Doctors Receiving Payments for NOCDURNA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Urology | Homewood, AL | $8,375 | 30 |
| , MD | Urology | Austin, TX | $7,948 | 23 |
| , M.D | Urology | Monroeville, PA | $7,362 | 29 |
| , MD | Surgery | New York, NY | $6,813 | 11 |
| Joseph Verbalis | Endocrinology, Diabetes & Metabolism | Washington, DC | $6,780 | 10 |
| , M.D | Obstetrics & Gynecology | Weston, FL | $6,709 | 3 |
| , D.O | Specialist | Philadelphia, PA | $6,630 | 16 |
| , MD | Obstetrics & Gynecology | Oklahoma City, OK | $5,547 | 3 |
| , MD | Urology | Charleston, SC | $5,292 | 1 |
| , MD | Urology | New York, NY | $4,977 | 7 |
| , M.D | Psychiatry | Durham, NC | $4,761 | 9 |
| , MD | Urology | Springfield, IL | $3,905 | 5 |
| , PA.C | Physician Assistant | Los Angeles, CA | $3,847 | 25 |
| , M.D | Urology | Sherman Oaks, CA | $3,376 | 11 |
| , M.D | Family Medicine | Providence, RI | $3,307 | 4 |
| , M.D | Urology | Fulton, MD | $3,299 | 17 |
| , M.D | Endocrinology, Diabetes & Metabolism | Baltimore, MD | $3,132 | 2 |
| , MD | Urology | New York, NY | $3,086 | 2 |
| , M.D | Urology | Houston, TX | $3,031 | 2 |
| , MD | Urology | Charleston, SC | $3,000 | 1 |
| , MD | Urology | Philadelphia, PA | $3,000 | 1 |
| , MD | Hospitalist | Passaic, NJ | $3,000 | 1 |
| , MD | Urology | Natick, MA | $2,211 | 11 |
| , MD | Urology | Santa Monica, CA | $2,162 | 18 |
| , M.D., F.R.C.S.C | Urology | New York, NY | $2,035 | 1 |
Manufacturing Companies
- Ferring Pharmaceuticals AS $2.5M
- Ferring International Pharmascience Center US $2.1M
- Antares Pharma, Inc. $890,146
- Ferring Pharmaceuticals Inc. $521,739
- Ferring International Center SA $96.38
Product Information
- Type Drug
- Total Payments $6.1M
- Total Doctors 12,343
- Transactions 39,483
About NOCDURNA
NOCDURNA is a drug associated with $6.1M in payments to 12,343 healthcare providers, recorded across 39,483 transactions in the CMS Open Payments database. The primary manufacturer is Ferring Pharmaceuticals AS.
Payment data is available from 2018 to 2023. In 2023, $210,090 was paid across 10,333 transactions to 6,082 doctors.
The most common payment nature for NOCDURNA is "Unspecified" ($4.6M, 76.3% of total).
NOCDURNA is associated with 2 research studies, including "A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults" ($2.5M).